100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
FA-MA106 Geneesmiddelontwerp Productdossier p3 $13.50   Add to cart
Quickly navigate to
Preview
  2.  
  3. Universiteit Utrecht (UU)
  4.  
  5. FA-MA106 (FAMA106)

Essay

FA-MA106 Geneesmiddelontwerp Productdossier p3

1 review
 61 views  4 purchases
  • Course
  • FA-MA106 (FAMA106)
  • Institution
  • Universiteit Utrecht (UU)

Dit is het productdossier dat ik heb moeten maken voor FA-MA106. Ik heb deze cursus in collegejaar periode 3 gevolgd. Het kan zijn dat het vak sindsdien is veranderd en daarmee ook de bijbehorende opdracht over het dossier. *Ook in een bundel verkrijgbaar met een uitgebreide samenvatting van FA...

[Show more]

Preview 4 out of 46  pages

Document information

  • February 14, 2022
  • 46
  • 2020/2021
  • Essay
  • Unknown
  • 7-8

Subjects

  • geneesmiddel
  • ontwerp
  • design
  • geneesmiddelontwerp
  • fa ma
  • farmacie
  • master
  • productdossier
  • dossier
  • cbv
  • fa ma106

Written for

  • Universiteit Utrecht (UU)
  • Farmacie
  • FA-MA106 (FAMA106)
All documents for this subject (2)

1  review

review-writer-avatar

By: FarmacieArchief • 6 months ago

Seller

avatar-seller
Michelle1802

Reviews received

Content preview

FA-MA106
Geneesmiddelontwerp
Dossier
M. de Leeuw
29 mei 2021

,FA-MA106 Geneesmiddelontwerp dossier M. de Leeuw



Inhoud
1.Midazolam infuus 1 mg/ml, 100 ml ............................................................................................................. 5
1.1.Casus 2C ................................................................................................................................................ 5
1.2.Voorstel geneesmiddelontwerp ............................................................................................................ 5
1.2.1.Het product .................................................................................................................................... 5
1.2.2.Toedieningsroute ........................................................................................................................... 5
1.2.3.Verpakking...................................................................................................................................... 5
1.2.4.Kritische ontwerpaspecten ............................................................................................................ 5
1.3.Eigenschappen farmacon ...................................................................................................................... 5
1.3.1.Fysisch-chemische eigenschappen van midazolam ....................................................................... 5
1.3.2.Farmacokinetische eigenschappen van midazolam ....................................................................... 6
1.3.3.Farmacodynamische eigenschappen van midazolam .................................................................... 7
1.4.Doseringscontrole ................................................................................................................................. 7
1.4.1.Dosering ......................................................................................................................................... 7
1.4.2.Infusiesnelheid ............................................................................................................................... 7
1.5.Rationale ............................................................................................................................................... 7
1.6.Formulering ........................................................................................................................................... 8
1.7.Berekeningen ........................................................................................................................................ 8
1.7.1. Hoeveelheid infuus........................................................................................................................ 8
1.7.2. Hoeveelheid midazolam HCl ......................................................................................................... 8
1.7.3. Hoeveelheid NaCl; isotonie berekening ........................................................................................ 8
1.8.Veiligheidsaspecten............................................................................................................................... 9
1.9.Stabiliteit en houdbaarheid................................................................................................................... 9
1.9.1.Chemische stabiliteit ...................................................................................................................... 9
1.9.2.Fysische stabiliteit ........................................................................................................................ 10
1.9.3.Microbiologische stabiliteit .......................................................................................................... 10
1.9.4.Houdbaarheid............................................................................................................................... 10
1.10.Conclusie/voorstel tot wijzigen ......................................................................................................... 10
1.11.CBV .................................................................................................................................................... 11
1.12.CBP .................................................................................................................................................... 12
1.13.Discussie ............................................................................................................................................ 14
2.Spironolacton suspensie 1 mg/ml, 100 ml ................................................................................................. 17
2.1.Casus 3C .............................................................................................................................................. 17
2.2.Voorstel geneesmiddelontwerp .......................................................................................................... 17
2.2.1.Het product .................................................................................................................................. 17
2.2.2.Toedieningsroute ......................................................................................................................... 17
2.2.3.Verpakking.................................................................................................................................... 17

Universiteit Utrecht Pagina 2 van 46

,FA-MA106 Geneesmiddelontwerp dossier M. de Leeuw


2.2.4.Kritische ontwerpaspecten .......................................................................................................... 17
2.3.Eigenschappen farmacon .................................................................................................................... 17
2.3.1.Fysisch-chemische eigenschappen van spironolacton ................................................................. 17
2.3.2.Farmacokinetische eigenschappen van spironolacton ................................................................ 18
2.3.3.Farmacodynamische eigenschappen van spironolacton ............................................................. 19
2.4.Doseringscontrole ............................................................................................................................... 19
2.5.Rationale ............................................................................................................................................. 19
2.6.Formulering ......................................................................................................................................... 20
2.7.Berekeningen ...................................................................................................................................... 20
2.8.Veiligheidsaspecten............................................................................................................................. 21
2.9.Stabiliteit en houdbaarheid................................................................................................................. 21
2.9.1.Chemische stabiliteit .................................................................................................................... 21
2.9.2.Fysische stabiliteit ........................................................................................................................ 21
2.9.3.Microbiologische stabiliteit .......................................................................................................... 22
2.9.4.Houdbaarheid............................................................................................................................... 22
2.10.Conclusie/voorstel tot wijzigen ......................................................................................................... 22
2.11.CBV .................................................................................................................................................... 23
2.12.CBP .................................................................................................................................................... 25
2.13.Discussie ............................................................................................................................................ 27
3.Natamycine ................................................................................................................................................ 29
3.1.Casus 4C .............................................................................................................................................. 29
3.2.Voorstel geneesmiddelontwerp .......................................................................................................... 29
3.2.1.Het product .................................................................................................................................. 29
3.2.2.Toedieningsroute ......................................................................................................................... 29
3.2.3.Verpakking.................................................................................................................................... 29
3.2.4.Kritische ontwerpaspecten .......................................................................................................... 29
3.3.Eigenschappen farmacon .................................................................................................................... 29
3.3.1.Fysisch-chemische eigenschappen van natamycine .................................................................... 29
3.3.2.Farmacokinetische eigenschappen van natamycine .................................................................... 30
3.3.3.Farmacodynamische eigenschappen van natamycine ................................................................. 30
3.4.Doseringscontrole ............................................................................................................................... 30
3.5.Rationale ............................................................................................................................................. 31
3.6.Formulering ......................................................................................................................................... 31
3.7.Berekeningen ...................................................................................................................................... 31
3.8.Veiligheidsaspecten............................................................................................................................. 32
3.9.Stabiliteit en houdbaarheid................................................................................................................. 33
3.9.1.Chemische stabiliteit .................................................................................................................... 33


Universiteit Utrecht Pagina 3 van 46

, FA-MA106 Geneesmiddelontwerp dossier M. de Leeuw


3.9.2.Fysische stabiliteit ........................................................................................................................ 33
3.9.3.Microbiologische stabiliteit .......................................................................................................... 33
3.9.4.Houdbaarheid............................................................................................................................... 34
3.10.Conclusie/voorstel tot wijzigen ......................................................................................................... 34
3.11.CBV .................................................................................................................................................... 35
3.12.CBP .................................................................................................................................................... 37
3.13.Discussie ............................................................................................................................................ 39
4.Bronnen ...................................................................................................................................................... 42
5.Bijlagen ....................................................................................................................................................... 44
5.1.Bijlage I: Origineel CBP midazolam infuus ........................................................................................... 44
5.2.Bijlage II: Origineel CBP spironolacton suspensie ............................................................................... 45
5.3.Bijlage III: Origineel CBP natamycine oogdruppels ............................................................................. 46




Universiteit Utrecht Pagina 4 van 46

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Michelle1802. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $13.50. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

67096 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$13.50  4x  sold
  • (1)
  Add to cart